logo
Anyone Can Get Head Lice — It Doesn't Matter How Often You Wash Your Hair

Anyone Can Get Head Lice — It Doesn't Matter How Often You Wash Your Hair

Health Line21-05-2025
The myth that head lice prefer unwashed hair has fueled plenty of stigma. In reality, there's no link between these tiny parasites and personal hygiene. Anyone can get them.
Getting head lice doesn't mean your hair, or any other part of your body, is 'dirty.'
Even though some insects are attracted to unclean places, that's not the case for head lice. These parasites feed on blood, and anyone can acquire them. According to experts, it doesn't make a difference if you recently washed your hair or not.
Lice are incredibly common around the world. Estimates suggest that each year, between 6 and 12 million infestations affect kids ages 3 to 11 in the United States.
Read on to learn more about head lice spread, how to treat infestations, and what you can do to avoid getting head lice.
Who is more likely to get lice?
While you can get head lice at any age, lice do tend to affect children more often than adults. This may be because children tend to play closely, with their heads touching, and lice move from one scalp to the next through close head-to-head contact.
Lice also tend to be more common in girls. Experts say this may happen because girls are more likely to play with their heads close together. Hair length doesn't have any effect on your risk of getting head lice.
That said, you may have a harder time finding lice and their eggs (nits) in thick, long, natural, or curly hair. This has fueled a myth that people with coiled, curly hair can't get lice. In reality, people with any hair type or texture can get lice.
How can you prevent head lice?
Head lice don't care how often you shower or wash your hair. There's no tried-and-true way to prevent head lice, but you can take steps to lower your risk. Here are some recommendations:
Avoid close head-to-head contact: Lice often spreads due to close contact at slumber parties, contact sports, and children's games. Just keep in mind, you won't get lice simply by standing near someone who has lice.
Avoid sharing clothing or accessories that touch your hair: It's possible to transmit lice by sharing hats, hair ties, barrettes, scarves, and coats — anything that has prolonged contact with your head and hair.
Avoid sharing brushes, combs, or other hair styling accessories: These items may also transmit lice, but this is less common. If you do share these items, you can kill lice by soaking them in hot water (at least 130°F, or 54°C) for 5 to 10 minutes.
Avoid lying on communal couches, beds, pillows, and stuffed animals: Lice can live in bedding and furniture for up to 2 days.
Always wash and dry bedding, clothing, and other items: If someone in your home has head lice, you can kill any lice in these items by washing them in hot water and drying them on high heat. If you can't wash something, you can dry clean it, or seal it in a plastic bag for 14 days to make sure all the nits (lice eggs) die.
Vacuum your furniture and floor: Pay careful attention to carpeted areas, rugs, and furniture like sofas and chairs.
What's the best way to treat head lice?
You can't kill head lice by washing your hair with shampoo. If you have live lice or lice eggs in your hair, you'll need to use a special lice treatment.
Over-the-counter (OTC) options approved by the Food and Drug Administration (FDA) include:
Permethrin 1% (Nix): Permethrin 1% is safe for children of all ages, including babies more than 2 months old. If your child under 2 months has lice, consider consulting a pediatrician.
Pyrethrins and piperonyl butoxide (Pronto, Rid): You can use pyrethin treatments for children ages 2 and up, but avoid this option if you're allergic to chrysanthemums or ragweed.
Both of these treatments kill live lice but not unhatched eggs. A second treatment, roughly a week after the first, can kill newly hatched lice.
You can also ask a doctor about prescription treatments, such as:
Benzoyl alcohol 5% (Ulesfia): This treatment kills lice but not unhatched eggs. You'll need to treat your hair again about a week later.
Ivermectin 0.5% (Sklice): This treatment kills lice and seems to prevent newly hatched lice from living.
Malathion 0.5%: This treatment kills live lice and some lice eggs. You may need a second treatment to kill any lice still living 7 to 9 days after treatment. It's only approved for use on those ages 6 and up.
Spinosad 0.9%: This treatment kills live lice and unhatched eggs. Re-treatment isn't usually necessary. It's only approved for use on those ages 6 and up.
If these methods don't get rid of head lice, your doctor may recommend trying lindane 1%.
As this treatment is strong, experts only recommend it if other treatments are ineffective. If you use too much or swallow some by mistake, it may harm your brain or nervous system. Use this treatment once.
This treatment isn't safe for:
babies or children
pregnant or nursing people
older adults
people who weigh under 110 pounds
those living with HIV or seizures
people who have sores or skin irritation on the application site
Whichever treatment option you choose, consider checking your hair every 3 to 14 days after applying a treatment to ensure its effectiveness.
Can you use home remedies instead of OTC treatments?
As an alternative to OTC or prescription treatments, you can manually comb out the lice and nits with a fine-toothed comb or a specially designed lice comb. Applying olive oil to the hair can help capture the lice and nits.
You'll need to repeat this at least every 2 to 3 days until all lice and eggs disappear — but keep in mind that experts say this may not work as a stand-alone treatment.
Learn more about home remedies for head lice.
Takeaway
Anyone can get lice — no matter where you live, how old you are, or how often you wash your hair. Since lice feed on blood in your scalp, it doesn't matter whether your hair is freshly shampooed or not.
If you or your child has lice, washing your hair or your child's hair with shampoo will not help. An effective OTC or prescription treatment can help you get rid of head lice, though certain treatments may require more than one application.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run
2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run

Yahoo

timean hour ago

  • Yahoo

2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run

Key Points Hims & Hers Health is unlocking new sources of growth potential, and its balance sheet is flourishing. Doximity is a prime platform for advertisers, and the profits are pouring in. 10 stocks we like better than Hims & Hers Health › It's been a wild first half of the year for stocks in 2025, but finding the right companies for your portfolio is a very personal process. You need to consider the type of stocks you want to buy, the industries and sectors you gravitate toward, the amount of capital you have to invest, and your own personal risk tolerance. If you have cash to invest in the stock market right now, and you're looking for growth stocks that could make smart additions to the basket of businesses you own, there are names to be found across a range of industries, including healthcare. Here are two healthcare stocks that have at least doubled over the past 12 months but still look poised to deliver favorable returns for shareholders in the next three to five years. 1. Hims & Hers Health Hims & Hers Health (NYSE: HIMS) has witnessed a stock run-up of more than 200% over the trailing-12-month period. In contrast, the S&P 500 is up only about 18% in that same time frame. This boom in the company's share price has occurred for a few reasons. Investors were particularly excited about the company's ability to offer affordable, compounded GLP-1 drugs for weight loss amid shortages of branded versions, and that fueled significant revenue growth and share-price appreciation. However, Hims & Hers can no longer mass-produce compounded drugs like semaglutide because the U.S. Food and Drug Administration declared the shortage resolved. While the company may still offer personalized doses where clinically applicable, its primary weight loss offerings are shifting to oral medications and liraglutide. In fact, Novo Nordisk, the maker of Wegovy (semaglutide for weight) and Ozempic (semaglutide for diabetes), ended its partnership with Hims & Hers, citing concerns over the latter company's promotion and sales of compounded semaglutide. While the company's offerings may evolve in the coming months and years, it has other sources of growth to lean on besides the weight loss segment. Hims & Hers' areas of focus include sexual health, hair loss, dermatology, mental health, and primary care. The platform also provides access to both over-the-counter and prescription treatments via online consultations with licensed healthcare professionals, and most of its revenue still comes from recurring subscriptions paid by healthcare consumers. The recent acquisition of Zava, a European digital health platform, seems to have boosted investor confidence in the future of the business outside of its ambitions in the weight loss industry. The addition of Zava to Hims & Hers' ecosystem will expand its reach into the U.K., Ireland, France, and Germany. Hims & Hers also plans to launch its platform in Canada in 2026. Revenue grew by 110% year over year in the first quarter, and the company is building upon an improving track record of profitability. Hims & Hers also delivered free cash flow of about $50 million in Q1. This business has a lot of potential. 2. Doximity Doximity (NYSE: DOCS) has seen shares pop by a bit more than 100% since this time one year ago. Doximity is known as the largest digital platform for U.S. medical professionals. It serves as a professional and social network for healthcare professionals including doctors, nurse practitioners, and physician assistants, and offers a wide variety of tools for communication, news, and career management. Doximity provides a curated newsfeed with the latest medical news and research relevant to different specialties, and also offers tools for job searches, salary comparisons, and reputation management. The platform even provides telehealth solutions, enabling virtual patient visits and consultations. The platform is free for healthcare professionals to use. This free access includes Doximity Dialer, a feature that allows secure communication with patients using a customized calling tool. The platform also offers free digital fax lines and access to Doximity Scribe, an AI-powered note-taking tool for verified clinicians. So, how does Doximity make money? From advertising and selling information. Doximity's platform is a prime digital marketing and advertising tool for pharmaceutical manufacturers and healthcare systems (like hospitals). These entities pay Doximity to advertise and promote their products and services to targeted medical professionals. Health systems and medical recruiting firms also pay Doximity to access its database of medical professionals for recruitment and hiring purposes. In Doximity's fiscal 2025, which ended March 31, revenue increased 20% from the prior fiscal year to $570.4 million. The company reported net income of $223.2 million, up 51% year over year, with free cash flow spiking 50% to $266.7 million. This healthcare stock is really an advertising business at its core, and a profitable one at that. These factors could induce some investors to take another long look at this top stock and I think it has room to run. Do the experts think Hims & Hers Health is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Hims & Hers Health make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,019% vs. just 178% for the S&P — that is beating the market by 841.12%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Rachel Warren has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Doximity and Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Healthcare Stocks That Have Doubled Over the Last Year but Still Have Room to Run was originally published by The Motley Fool 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤

Deion Sanders says he never questioned God during his battle with bladder cancer
Deion Sanders says he never questioned God during his battle with bladder cancer

Fox News

timean hour ago

  • Fox News

Deion Sanders says he never questioned God during his battle with bladder cancer

Deion Sanders revealed Monday he had his bladder removed after he was diagnosed with cancer, but he said he never questioned God, no matter how difficult things were. Sanders, 57, said God has blessed him too much to ask, 'Why me?' "I have never questioned God. You know my faith, man," Sanders said during an interview with Michael Irvin. "I never questioned and ask God. 'Why me?' I can't. Why me am I living like this? Why me am I the coach of the Colorado Buffaloes? Why me am I on this wonderful university? Why me do I have these wonderful kids with my last name? Like, why me that God has blessed me so much. Like, I would have to ask God, 'Why me all that, too?' "So, I never asked God, 'Why me?'" Sanders said he only asked the Lord to show him the way. "I only said, 'Lord, show me. Show me what you trying to do so I can help you expedite the process. Just show me. We got this, Lord. I know I ain't going nowhere,'" Sanders said. "I know for the enemy to try me, you had to say, 'Have you considered my servant crime?' You had to say that for him to even get to me. So I know that, I'm yours. I know what you going to do with me. I know what you going to continue to do with me." The bladder removal has forced Sanders to undergo a complete lifestyle change, which he said he reached out to someone for advice on how to deal with the changes. Sanders urged people to get checked, because he only discovered the cancer in the bladder after an ACT scan of his vascular pattern to determine if his blood clots were away. The Colorado head coach said it was "unbelievable" to be back talking to his players again. Colorado went 9-4 last season and will look to improve on that record this season after losing Heisman Trophy winner Travis Hunter and starting quarterback Shedeur Sanders to the NFL.

Option Care Health, Inc. (OPCH): A Bull Case Theory
Option Care Health, Inc. (OPCH): A Bull Case Theory

Yahoo

timean hour ago

  • Yahoo

Option Care Health, Inc. (OPCH): A Bull Case Theory

We came across a bullish thesis on Option Care Health, Inc. on Brian's Substack by Brian Flasker. In this article, we will summarize the bulls' thesis on OPCH. Option Care Health, Inc.'s share was trading at $29.35 as of July 31st. OPCH's trailing and forward P/E were 23.29 and 19.65, respectively according to Yahoo Finance. A home infusion nurse in full PPE gown delivering treatments to a patient in their own home. Option Care Health (OPCH) has evolved into the dominant independent provider of home and alternate site infusion services in the U.S., originating from Madison Dearborn Partners' 2015 acquisition of Walgreens Infusion Services. The 2019 reverse merger with BioScrip and full divestiture by Walgreens and MDP by 2023 paved the way for OPCH to operate with full independence. Led by CEO John Rademacher and CFO Michael Shapiro, both with substantial equity stakes, OPCH has built a national infrastructure of 91 pharmacies and 99 infusion suites, covering 96% of the U.S. population. The company's integrated model provides cost-effective, high-quality infusion therapies in outpatient and home settings, capitalizing on a healthcare trend shifting treatments away from costly hospitals. This platform serves over 1,400 contracts with 800+ partners, including all top 10 national insurers. Acute therapies, though operationally complex, act as a competitive wedge, while chronic therapies anchor long-term recurring revenues. OPCH's mix—75% chronic, 25% acute—combined with a focus on generics and biosimilars, ensures resilience against pricing volatility. With its Advanced Practitioner (AP) model, OPCH is pushing clinical boundaries, managing more complex therapies in lower-cost settings and enhancing utilization of its already-built infrastructure. Only ~50% of its infusion suite capacity is currently utilized, leaving ample runway for capital-light growth. Despite industry concerns like drug pricing reforms and labor shortages, OPCH's embedded relationships, clinical capabilities, and scalable model offer strong visibility into cash flow and earnings. Trading at ~15.4x 2025 owner earnings with a 17.4% expected IRR, OPCH represents a high-quality compounder with an entrenched moat and significant upside. Previously, we covered a bullish thesis on Chemed Corporation by 310 Value in April 2025, which highlighted the durability of its earnings, temporary volatility in its subsidiaries, and disciplined share repurchases. The company's stock price has depreciated by approximately 29% since our coverage. This is because temporary segment headwinds persisted longer than expected. The thesis still stands as Chemed's core fundamentals remain intact. Brian Flasker shares a similar view but emphasizes OPCH's capital-light model and payer-aligned infrastructure. Option Care Health, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 40 hedge fund portfolios held OPCH at the end of the first quarter, which was 40 in the previous quarter. While we acknowledge the potential of OPCH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store